Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 in R/R Waldenstrom Macroglobulinemia
NCT04440059Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Aug 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in Waldenstrom macroglobulinemia (WM), sponsored by InnoCare Pharma. Started Aug 2019; status: completed.
02
Drugs
orelabrutinib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04440059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440059.